Navigation Links
Pharmacyclics Reports Financial Results and Recent Developments for Fiscal Year and Fourth Quarter 2011 - Conference Call Set for Today at 4:30 PM EDT
Date:9/12/2011

ecause of bone marrow or other organ toxicity are demanded.  In the aggressive lymphomas, it is our belief that the need exists for agents that can combine with standard therapies to improve cure rate, and for agents that are effective in patients that fail potentially curative therapy.

In the major pharmaceutical markets in the US, Europe and Japan, Decision Resources, Inc. estimates the following for 2011: There are 305,440 prevalent cases living with DLBCL (prevalence is defined as people living with a history of the disease at a particular point in time), with 50,180 patients estimated to be in the first line setting (these are newly diagnosed cases) and 34,320 patients estimated to be in the relapsed/refractory setting. CLL/SLL constitutes about one-third of the B-cell malignancy population. There are 172,630 prevalent cases living with CLL, with 39,390 patients estimated to be in the first line setting and 33,550 patients estimated to be in the relapsed/refractory CLL setting. Follicular lymphoma (FL) constitutes about 20% of the B-cell malignancy population and is considered an indolent, yet incurable, disease. There are 136,450 prevalent cases living with FL, with 21,050 patients estimated to be in the first line setting and 14,270 patients estimated to be in the relapsed/refractory setting.  MCL, generally an aggressive form of lymphoma, comprises approximately 5% of the newly diagnosed B-cell malignancies. There are 32,180 prevalent cases living with MCL, with 5,300 patients estimated to be in the first line setting and 4,140 patients estimated to be in the relapsed/refractory setting.

There are many distinct subtypes of B-cell malignancies; the common ones include the following: follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma. The NHL therapy market will experience robust annual growth (7.6% per year) and more than double in size over the years 2
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pharmacyclics Announces Date of Fiscal Year End 2011 Financial Results and Conference Call
2. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
3. Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings
4. Pharmacyclics to Announce Third Quarter Fiscal 2011 Results and Host a Conference Call on May 4, 2011
5. Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011
6. Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human Btk-Inhibitor PCI-32765
7. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
8. Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
9. Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference
10. Pharmacyclics to Present at Bank of America Merrill Lynch Healthcare Conference and MDB Bright Lights Conference
11. Pharmacyclics to Present at the RBC Capital Markets Healthcare Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... company specializing in oncology, today announced that David ... at BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on ... Time. The conference will take place at the Millennium ... . A live and archived webcast of ...
(Date:9/18/2014)... 18, 2014  Low T Center endorses the ... Hyattsville, Maryland earlier this ... proper patient population for testosterone therapy (TRT), as ... with TRT. Examining recent claims from studies that TRT ... epidemiological studies do not provide convincing evidence that ...
(Date:9/18/2014)... , Sept. 18, 2014   MacPractice,s MacPractice ... Edition Complete EHR certification, which designates that the software ... Stage 1 and Stage 2 Meaningful Use measures required ... Reinvestment Act (ARRA).  MacPractice MD MU version 5.0 was ... , an Office of the National Coordinator-Authorized Certification Body ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... 2011 Heska Corporation (NASDAQ: ... veterinary diagnostic and other specialty veterinary products , today ... best practices research, tools and metrics for patent analysis ... Heska,s Science Strength in the top 50 of the ...
... released by SCM: (Photo:   http://photos.prnewswire.com/prnh/20111006/LA81891 ) ... of closing statements, lead trial attorney for the plaintiffs in ... asked jurors to bring a verdict of $10 million in ... for James Arnold and to consider whether the Arnolds should ...
Cached Medicine Technology:The Patent Board, IP Tracking and Analysis Firm, Ranks Heska's Science Strength in Biotechnology Industry Top 50 2Lead Trial Attorney in Clark County Hepatitis C Trial, Robert Eglet, Asks Jury to Award $10 Million Compensatory Damages for Anne Arnold, $2.5 Million for James Arnold 2
(Date:9/19/2014)... 2014 United Benefit Advisors (UBA), ... its annual Fall Meeting & Expo at the ... Illinois. With a fantastic attendance of more ... new CEO, Les McPhearson, led these thought leaders ... what is required of successful advisor firms looking ...
(Date:9/19/2014)... September 19, 2014 Script Relief, ... on all commonly prescribed high blood pressure medications. ... drug coupons and has saved its users over ... of making prescription medications more accessible and affordable, ... blood pressure medications. , High blood pressure, also ...
(Date:9/19/2014)... Indiana Fiber Network, LLC (IFN), the leading Indiana ... Fiber Transport Services, adding Point of Presence (PoP) at ... PoP at Cermak, IFN enables interconnect opportunities for Carriers, ... fiber transport service to US and Global Carriers. ... Sales and Marketing August Zehner, establishing a PoP at ...
(Date:9/19/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Potassium Chloride . , The FDA announced on ... lot of Potassium Chloride Injection 10mEq per 100mL due to ... intravenously, is used to treat potassium deficiency. , The ... on the shipping cartons in a single lot where, for ...
(Date:9/19/2014)... A McLean County woman filed ... following a failed hip replacement using a DePuy XL ... Inc. and Johnson & Johnson over allegations that they ... nationally known personal injury law firm, represents defective hip ... involving defective hips. , According to the lawsuit, Owens ...
Breaking Medicine News(10 mins):Health News:United Benefit Advisors New CEO Presides Over Fall Meeting & Expo 2Health News:United Benefit Advisors New CEO Presides Over Fall Meeting & Expo 3Health News:HelpRx.info Now Providing Discounts on All Common High Blood Pressure Medications 2Health News:HelpRx.info Now Providing Discounts on All Common High Blood Pressure Medications 3Health News:Indiana Fiber Network Launches Point-Of-Presence in Chicago Data Center at Cermak 2Health News:Baxter Recalls Potassium Chloride Injection: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Flood Law Group Comments on Recent Hip Replacement Lawsuit 2
... ... Fresh, Nutritious, and Creative , ... Santa Cruz, CA (Vocus) June 18, 2010 -- School’s about to start and so ... J? Switch it up with kids’ bento boxes , from Laptop Lunches. ...
... ... people of all faiths in Dallas, TX, on June 27th and 28th, 2010. Spiritual ... her love and compassion in person. , ... Dallas, TX (PRWEB) June 18, 2010 -- The ‘Hugging Saint’ Amma ( http://www.amma.org ...
... ... their new 360 Degree Guarantee and provide consumers with coverage that extends past the original ... by a standard warranty. , ... (PRWEB) June 18, 2010 -- Treadmill Doctor has announced the introduction of their ...
... ... barometer for hiring this fall, we are about to see a significant pickup in recruiting from ... (PRWEB) June 18, 2010 -- ... leading indicator for future hiring activity. “It only makes sense, says RD Whitney, CEO of Onrec ...
... ... industry lived up to its tagline - “Connecting you to good health” when it successfully ... , ... Makewell Meditour Ltd., a pioneer in India’s medical tourism industry lived up to ...
... trial of a new model for testing Alzheimer,s treatments has ... exacerbate the disease if treatment is interrupted. Scientists at ... & Co. Inc studied the effects of a class of ... these drugs might cause a build-up of proteins linked to ...
Cached Medicine News:Health News:Kids' Lunchboxes Go Bento for Easy Back to School Lunch Making, Thanks to Laptop Lunches 2Health News:The ‘Hugging Saint' Amma Visits Dallas June 27-28, 2010, Offering Spiritual Upliftment to People of All Faiths 2Health News:Treadmill Doctor 360 Degree Guarantee Extended Service Plans 2Health News:Onrec Predicts Significant Recruiting Activity this Fall 2Health News:Onrec Predicts Significant Recruiting Activity this Fall 3Health News:Onrec Predicts Significant Recruiting Activity this Fall 4Health News:Makewell Meditour Helps Nigerian Family Find a Facility to Perform Rare Separation Surgery for Conjoined Twins 2Health News:Makewell Meditour Helps Nigerian Family Find a Facility to Perform Rare Separation Surgery for Conjoined Twins 3Health News:New model suggests feared side effect of Alzheimer's drugs is unlikely 2
Upon application to intact skin, Skin-Prep* protective wipes forms a protective film that prepares the skin for the attachment of drainage tubes, external catheters, adhesive dressings and can be...
Triad Plus Sterile Isopropyl Alcohol 70% USP Prep Pads are medium size. Each package is terminally sterilized, ensuring the safest possible product....
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
... Triad Plus Sterile ... Swabsticks are primarily used ... prior to administering injections. ... to meet AAMI/ANSI/ISO 11137 ...
Medicine Products: